Impact of gut microbiome on skin health: gut-skin axis observed through the lenses of therapeutics and skin diseases
10.1080/19490976.2022.2096995 · doi-reference
Genome-scale metabolic reconstruction of 7,302 human microorganisms for personalized medicine
10.1038/s41587-022-01628-0 · doi-reference
A core microbiome signature as an indicator of health
10.1016/j.cell.2024.09.019 · doi-reference
The healthy microbiome-what is the definition of a healthy gut microbiome?
10.1053/j.gastro.2020.09.057 · doi-reference
An international perspective on the future of systemic sclerosis research
10.1038/s41584-024-01217-2 · doi-reference
Larazotide acetate: a pharmacological peptide approach to tight junction regulation
10.1152/ajpgi.00386.2020 · doi-reference
Role of vitamin D in systemic sclerosis: a systematic literature review
10.1155/2021/9782994 · doi-reference
Protective effects of vitamin D against injury in intestinal epithelium
10.1007/s00383-019-04586-y · doi-reference
Using gut microbiota and non-targeted metabolomics techniques to study the effect of xylitol on alleviating DSS-induced inflammatory bowel disease in mice
10.1186/s12865-025-00700-z · doi-reference
Bifidobacterium animalis subsp. lactis GOLDGUT-BB69 counteracts diarrhea in mice by alleviating inflammation, enhancing intestinal barrier functions, and regulating intestinal microbiota
10.1007/s12602-025-10847-1 · doi-reference
Probiotic interventions maintain intestinal barrier function and alleviate necrotizing enterocolitis by inhibiting ferroptosis in intestinal PMN-MDSCs
10.1038/s41419-026-08869-w · doi-reference
Berberine treats atherosclerosis via a vitamine-like effect down-regulating choline-TMA-TMAO production pathway in gut microbiota
10.1038/s41392-022-01027-6 · doi-reference
Gut microbial signatures associated with clinical remission in inflammatory bowel disease treated with biologics: a comprehensive multi-cohort analysis
10.1002/ueg2.70064 · doi-reference
The total gut mucosal and fecal bacterial load increases in successful treatment of inflammatory bowel disease with infliximab
10.1128/spectrum.01894-24 · doi-reference
Methotrexate impacts conserved pathways in diverse human gut bacteria leading to decreased host immune activation
10.1016/j.chom.2020.12.008 · doi-reference
An expansion of rare lineage intestinal microbes characterizes rheumatoid arthritis
10.1186/s13073-016-0299-7 · doi-reference
Analysis of gut microbiota in rheumatoid arthritis patients: disease-related Dysbiosis and modifications induced by Etanercept
10.3390/ijms19102938 · doi-reference
Detection of increased relative expression units of Bacteroides and Prevotella, and decreased Clostridium leptum in stool samples from Brazilian rheumatoid arthritis patients: a pilot study
10.3390/microorganisms7100413 · doi-reference
The oral and gut microbiomes are perturbed in rheumatoid arthritis and partly normalized after treatment
10.1038/nm.3914 · doi-reference
Introduction: understanding mechanisms of the actions of rifaximin in selected gastrointestinal diseases
10.1111/apt.13406 · doi-reference
Rifaximin and alternative agents in the management of irritable bowel syndrome: a comprehensive review
10.1002/ardp.202400356 · doi-reference
Broad-spectrum antibiotic treatment reshapes the gut microbiome, resistome, and colonization potential of opportunistic pathogens: a metagenomics study
10.1186/s13099-026-00795-8 · doi-reference
Transforming medicine with the microbiome
10.1126/scitranslmed.aaw1815 · doi-reference
Drug-Resistant E. Coli bacteremia transmitted by fecal microbiota transplant
10.1056/nejmoa1910437 · doi-reference
Key determinants of success in fecal microbiota transplantation: from microbiome to clinic
10.1016/j.chom.2023.03.020 · doi-reference
Fecal microbiota transplantation in the treatment of systemic lupus erythematosus: what we learnt from the explorative clinical trial
10.1016/j.jaut.2023.103058 · doi-reference
Fecal microbiota transplantation: emerging applications in autoimmune diseases
10.1016/j.jaut.2023.103038 · doi-reference
Gut microbiome-targeted therapies in nonalcoholic fatty liver disease: a systematic review, meta-analysis, and meta-regression
10.1093/ajcn/nqz042 · doi-reference
Prebiotics, probiotics, fermented foods and cognitive outcomes: a meta-analysis of randomized controlled trials
10.1016/j.neubiorev.2020.07.036 · doi-reference
Postbiotics: an insightful review of the latest category in functional biotics
10.1007/s11274-025-04483-8 · doi-reference
Polyphenols-rich Portulaca oleracea L. (purslane) alleviates ulcerative colitis through restiring the intestinal barrier, gut microbiota and metabolites
10.1016/j.foodchem.2024.142391 · doi-reference
Role of dietary polyphenols on gut microbiota, their metabolites and health benefits
10.1016/j.foodres.2021.110189 · doi-reference
Potential for enriching next-generation health-promoting gut bacteria through prebiotics and other dietary components
10.1080/19490976.2019.1613124 · doi-reference
Expert consensus document: the international scientific Association for Probiotics and Prebiotics (ISAPP) consensus statement on the definition and scope of prebiotics
10.1038/nrgastro.2017.75 · doi-reference
Dietary simple sugars alter microbial ecology in the gut and promote colitis in mice
10.1126/scitranslmed.aay6218 · doi-reference
ILC3s regulate the gut microbiota via host intestinal galactosylation to limit pathogen infection in mice
10.1038/s41564-025-01933-9 · doi-reference
Akkermansia muciniphila ONE effectively ameliorates dextran sulfate sodium (DSS)-induced ulcerative colitis in mice
10.1038/s41538-024-00339-x · doi-reference
Akkermansia muciniphila: a key player in gut microbiota-based disease modulation
10.1016/j.micres.2025.128317 · doi-reference
Gut microbiome in systemic sclerosis: a potential therapeutic target
10.5114/ada.2020.101468 · doi-reference
Small intestinal bacterial overgrowth in patients suffering from scleroderma: clinical effectiveness of its eradication
10.1111/j.1572-0241.2007.01758.x · doi-reference
